Megan S Lim

Summary

Affiliation: University of Michigan
Country: USA

Publications

  1. pmc T cell lymphoproliferative disorders associated with anti-tumor necrosis factor alpha antibody therapy for ulcerative colitis: literature summary
    Lindsay A Schmidt
    Department of Pathology, M5240 Medical Science I, University of Michigan Medical School, 1301 Catherine Street, Ann Arbor, MI 48109 0602 USA
    J Hematop 2:121-6. 2009
  2. pmc Apoptosis of t(14;18)-positive lymphoma cells by a Bcl-2 interacting small molecule
    David R Abbott
    Department of Pathology, University of Michigan Medical School, M5242 Medical Science 1, 1301 Catherine, Ann Arbor, MI 48109 0602 USA
    J Hematop 2:113-9. 2009
  3. pmc Global phosphoproteomic profiling reveals distinct signatures in B-cell non-Hodgkin lymphomas
    Delphine Rolland
    Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan
    Am J Pathol 184:1331-42. 2014
  4. doi request reprint Concomitant BCR-ABL1 translocation and JAK2(V617F) mutation in three patients with myeloproliferative neoplasms
    Jennifer M Hummel
    Department of Pathology, University of Michigan, Ann Arbor, Michigan 48109 2200, USA
    Diagn Mol Pathol 21:176-83. 2012
  5. pmc Fusion peptides from oncogenic chimeric proteins as putative specific biomarkers of cancer
    Kevin P Conlon
    Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan 48109
    Mol Cell Proteomics 12:2714-23. 2013
  6. doi request reprint The proteomic signature of NPM/ALK reveals deregulation of multiple cellular pathways
    Megan S Lim
    Department of Pathology, University of Michigan, Ann Arbor, MI 48109, USA
    Blood 114:1585-95. 2009

Research Grants

  1. Proteomic biomarkers of ALK+ lymphoma
    Megan S Lim; Fiscal Year: 2010
  2. Proteomic biomarkers of ALK+ lymphoma
    Megan S Lim; Fiscal Year: 2011

Collaborators

Detail Information

Publications8

  1. pmc T cell lymphoproliferative disorders associated with anti-tumor necrosis factor alpha antibody therapy for ulcerative colitis: literature summary
    Lindsay A Schmidt
    Department of Pathology, M5240 Medical Science I, University of Michigan Medical School, 1301 Catherine Street, Ann Arbor, MI 48109 0602 USA
    J Hematop 2:121-6. 2009
    ..The spectrum of lymphoproliferative disorders associated with infliximab and the potential mechanisms by which they occur are discussed...
  2. pmc Apoptosis of t(14;18)-positive lymphoma cells by a Bcl-2 interacting small molecule
    David R Abbott
    Department of Pathology, University of Michigan Medical School, M5242 Medical Science 1, 1301 Catherine, Ann Arbor, MI 48109 0602 USA
    J Hematop 2:113-9. 2009
    ..Our findings further elucidate the cellular mechanisms accompanying Bcl-2 inhibition and demonstrate the potential of Bcl-2 inhibitors as therapeutic agents for the treatment of non-Hodgkin lymphomas...
  3. pmc Global phosphoproteomic profiling reveals distinct signatures in B-cell non-Hodgkin lymphomas
    Delphine Rolland
    Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan
    Am J Pathol 184:1331-42. 2014
    ..Overall, our study revealed the utility of unbiased phosphoproteome interrogation in characterizing signaling networks that may provide insights into pathogenesis mechanisms in B-cell lymphomas. ..
  4. doi request reprint Concomitant BCR-ABL1 translocation and JAK2(V617F) mutation in three patients with myeloproliferative neoplasms
    Jennifer M Hummel
    Department of Pathology, University of Michigan, Ann Arbor, Michigan 48109 2200, USA
    Diagn Mol Pathol 21:176-83. 2012
    ..The implications for diagnosis and treatment of patients with concomitant BCR-ABL1 and JAK2(V617F) are discussed as well as how the BCR-ABL1 and JAK2(V617F)-positive clones may be related to one another...
  5. pmc Fusion peptides from oncogenic chimeric proteins as putative specific biomarkers of cancer
    Kevin P Conlon
    Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan 48109
    Mol Cell Proteomics 12:2714-23. 2013
    ..Our studies highlight the utility of fusion peptides as cancer biomarkers and carry broad implications for the use of protein biomarkers in cancer detection and monitoring. ..
  6. doi request reprint The proteomic signature of NPM/ALK reveals deregulation of multiple cellular pathways
    Megan S Lim
    Department of Pathology, University of Michigan, Ann Arbor, MI 48109, USA
    Blood 114:1585-95. 2009
    ..Our studies carry important implications for the use of MS-driven approaches for the elucidation of neoplastic pathobiology, the identification of novel diagnostic biomarkers, and pathogenetically relevant therapeutic targets...

Research Grants2

  1. Proteomic biomarkers of ALK+ lymphoma
    Megan S Lim; Fiscal Year: 2010
    ..Collectively, our studies will lead to identification of protein biomarkers of NPM/ALK lymphomas that will be important for the diagnostic assessment, treatment and monitoring of patients with ALCL. ..
  2. Proteomic biomarkers of ALK+ lymphoma
    Megan S Lim; Fiscal Year: 2011
    ..Collectively, our studies will lead to identification of protein biomarkers of NPM/ALK lymphomas that will be important for the diagnostic assessment, treatment and monitoring of patients with ALCL. ..